Therapeutic strategies in RET gene rearranged non-small cell lung cancer
The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approac...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar and Chukwuemeka V. Ikpeazu Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Genetics | Hematology | Lung Cancer | Non-Small Cell Lung Cancer